{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9303","value":"6.2894"}]}],"title":"Poor Response"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.3814","value":"3.2720"}]}],"title":"Good Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The response is based on the Huvos grade of histologic response for DCE-MRI comparisons and is defined as good for ≥90% necrosis and poor for less than 90%.","dispersionType":"Standard Error","groups":[{"description":"Thirty-two participants with osteosarcoma were evaluated in this study. The analysis for this outcome measure included 23 Stratum A participants who had primary tumors potentially resectable by aggressive surgery, such as limb-salvage surgery or amputation, and no evidence of metastasis, and 8 Stratum C participants who had metastatic tumors.","id":"OG000","title":"All Participants"}],"paramType":"MEAN","populationDescription":"One participant with no histologic response but with evaluable imaging was excluded.","reportingStatus":"POSTED","timeFrame":"at week 10 after start of therapy","title":"Difference Between Good and Poor Response by SUVmax","type":"SECONDARY","unitOfMeasure":"(unitless)"}